We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dendritic Cross-Presentation Modulates Immune Response

By Biotechdaily staff writers
Posted on 04 Nov 2003
In a new study, researchers describe the mechanics of a pathway in dendritic cells responsible for the crosspresentation of antigens to T-cells when the immune system responds to invasion by pathogens.

When activated, CD8+ T cells become cytotoxic T lymphocytes (CTLs) and are responsible for eliminating virus-infected cells. More...
CTLs are able to recognize these cells because they display antigens on the cell surface as fragments of viral proteins (peptides) bound to major histocompatibility complex (MHC) class I molecules. Because of their aggressive nature and the risk of inflicting severe autoimmune diseases, the initial activation of CD8+ T-cells must be tightly controlled.

Therefore, while activated CTLs can recognize and kill any type of cell expressing the appropriate antigen, the activation of naive CD8+ T-cells requires the antigen to be initially presented by a specialized subset of bone marrow derived cells known as professional antigen presenting cells (pAPC). These cells are very mobile and can carry antigen from the peripheral tissues into the secondary lymphoid organs where naive CTLs reside. Importantly, pAPC do not necessarily need to be infected because they have a unique capacity to acquire antigen from other infected cells (antigen donor cells, ADC) in the process of crosspresentation.

The investigators, from the University of British Columbia (Vancouver, Canada), detected the existence of an endolysosomal compartment in dendritic cells where exogenously derived peptides could be acquired for presentation to T-cells, and showed that the MHC class I cytoplasmic domain contained a tyrosine-based targeting signal required for routing MHC class I molecules through these compartments. These findings were published October 19, 2003, in the online edition of Nature Immunology.

"This discovery opens the door to the immune system control room,” said senior author Dr. Wilfred Jefferies, professor of biotechnology at the University of British Columbia. "We have found a mechanism that appears to act like a dial. It can turn immune system response up or down.”


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.